TRLS-08. EXPERIENCE WITH THE SELECTIVE FIBROBLAST GROWTH FACTOR INHIBITOR ERDAFITINIB IN THREE PEDIATRIC PATIENTS WITH CNS TUMORS

Activation of FGF signaling has been described for at least 3% of pediatric solid tumors including pediatric gliomas. Therapeutic actionability of FGF signaling activations, however, remains challenging. Here, we report on three patients with FGFR activation treated with erdafitinib, originally appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stepien, Natalia, Mayr, Lisa, Hedrich, Cora, Lippolis, Maria Aliotti, Schned, Hannah, Baumgartner, Alicia, Raimann, Adalbert, Schmook, Maria-Theresa, Traub-Weidinger, Tatjana, Dorfer, Christian, Hartmann, Gabriele, Senfter, Daniel, Madlener, Sibylle, Peyrl, Andreas, Azizi, Amedeo A, Haberler, Christine, Müllauer, Leonhard, Gojo, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Translational Therapeutics/Clinical Trials - TRLS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259939/
http://dx.doi.org/10.1093/neuonc/noad073.311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259939/
http://dx.doi.org/10.1093/neuonc/noad073.311

Ejemplares similares